Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Adobe reported for the first quarter of fiscal year 2023

3/16/23 ADBE

Ticker EL5-Energo will change to ELFV

3/16/23 ELFV

Kamaz will develop a gas-powered SUV and bus for Gazprom

3/16/23 KMAZ

TCS Group extends pause in dividend payments

3/16/23 T

Cosmos Hotel Group took the largest five-star hotel in the North Caucasus under its management

3/16/23 AFKS

TCS Group's profits in 2022 decreased threefold

3/15/23 T

Rostelecom bought a software developer in the field of telecommunications networks

3/15/23 RTKM

Polyus will adhere to the divorce policy, but will also take into account changing economic conditions

3/15/23 PLZL

Polyus' 2022 profit fell by 33%

3/15/23 PLZL

Ozon created the largest logistics complex in Kazakhstan

3/15/23 OZON